Loading company
PharmaCyte Biotech, Inc.
PMCB · Nasdaq · ·
$0.42-3.6%Sep 29 close
- 1M
- -18.5%
- 6M
- -37.4%
- 1Y
- -56.7%
- 5Y
- -86.1%
PMCB · Nasdaq · ·
$0.42-3.6%Sep 29 close
The quarter ending July 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toJul 31, 2026 | 3 months toJul 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$5.1M | -$8.4M | +39.22% |
| Profit per share | -$0.54 | -$1.23 | +56.10% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
PharmaCyte Biotech, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from PharmaCyte Biotech, Inc.’s Item 2.02 8-K filed July 11, 2022; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.